Skip to main content

inHEART secures USD 11 million to optimise cardiac care

EIT Health-supported start-up, inHEART, has recently raised USD 11 million funding to drive commercial growth of its AI driven software solution for cardiac ablation procedures.

The company develops more advanced 3D cardiac models that can predict heart failure, sudden cardiac death, and cardio-embolic stroke caused by cardiac issues.

This new funding allows us to go further in addressing the needs of cardiac patients from early screening and disease detection through to advanced therapeutic support.

Todor Jeliaskov, Chairman and CEO of inHEART

About inHEART

Founded in 2017, inHEART is a deep tech, healthcare start-up based in Pessac, France (HQ) with a US subsidiary in Boston, who have developed the world’s first AI-driven, digital twin of the heart to advance the care of patients living with cardiac disease.

Addressing the challenges of conventional cardiac ablations, inHEART’s current solution creates highly detailed, interactive 3D heart models with proprietary AI-driven cardiac CT or MR image segmentation. These 3D models of the heart allow physicians to optimise treatment strategies based on each patient’s unique cardiac anatomy and to support pre-procedural planning for faster ablation procedures and improved clinical outcomes.

At inHEART, we are committed to addressing the needs of cardiac patients through early screening, disease detection, and advanced therapeutic support. We are proud to collaborate with EIT Health, which helps us improve our AI capabilities and gather additional clinical evidence. It’s exciting for EIT Health and inHEART to be at the forefront of transforming the healthcare industry with the power of AI technology by improving the efficiency of care, quality of decision-making, and effectiveness and safety of medical interventions.

Todor Jeliaskov, Chairman and CEO of inHEART

How EIT Health has supported inHEART

inHEART has participated in several EIT Health programmes and events: EIT Health Catapult and Summit in 2019, the Bridgehead programme and AI Health event in 2020, and Fast Track EIC in 2021 along with the 2021 Amplifier programme.

inHEART is the project leader in EIT Health’s start-up project inEurHeart which is an innovation project in 'Artificial Intelligence, Digital Twin & Clinical Trial for a Disruption in Catheter Ablation for Ventricular Tachycardia' and aims to optimise resource efficiency. Due to conclude in 2024, it is one of EIT Health's largest clinical studies with 14 study sites in France, Germany, Austria, and Switzerland.

EIT Health France has been delighted to support the inHEART team along their journey so far. Our EIT Health Accelerator and Venture Centre of Excellence (VCoE) colleagues have supported the company with access to finance support and expertise and have facilitated connections to our comprehensive network of pan-European partners. AI in health is a key priority today in Europe and beyond and inHEART plays a key role here as they develop AI tools to improve planning, accuracy and efficiency in surgery.

Marc Julien, Managing Director, France & Senior Director Accelerator